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Background/aim: Clinical exacerbations characterized with neurological symptoms are observed in around 10% of Behçet’s disease
(BD) patients and may culminate in severe disability. Although certain immunological factors have been associated with disease activity
in neuro-Behçet’s disease (NBD), biomarkers for monitoring the clinical outcome of NBD have not been properly investigated.
Materials and methods: Levels of neurofilament light chain (NFL), homeobox protein Hox-B3 (HoxB3), and YKL-40 were measured in
cerebrospinal fluid (CSF) samples of 23 parenchymal (n = 16) and nonparenchymal (n = 7) NBD patients obtained during NBD attacks
by ELISA. Parameters of clinical progression and outcome were assessed for an average follow-up period of 3.9 ± 1.3 years.
Results: Parenchymal NBD patients showed elevated CSF levels of NFL, HoxB3, and YKL-40 as compared to nonparenchymal patients.
NBD patients showing an increase in modified Rankin score (mRS) values during follow-up had significantly higher CSF NFL levels.
Patients with relatively lower CSF NFL levels (<1000 ng/L) did not develop attacks or cognitive impairment interfering with daily life
activities during follow-up. NFL levels correlated with disease duration and mRS at the last follow-up visit, while HoxB3 levels correlated
with a number of attacks during follow-up.
Conclusion: CSF level of NFL appears to predict the prospective somatic and cognitive disability in NBD patients and may thus be
potentially used as a biomarker of clinical outcome in this disease.
Key words: Neurofilament light, hoxB3, ykl-40, neuro-Behçet, prognosis

1. Introduction
Behçet’s disease (BD) is a multisystem inflammatory
disorder characterized by recurrent oral aphthae, genital
ulcerations, and uveitis [1]. Central nervous system (CNS)
involvement, which is named neuro-Behçet’s disease
(NBD) occurs in around 10% of BD patients and manifests
in parenchymal and vascular forms. While, in vascular
form, thrombosis of the dural sinus and cortical veins
are most often encountered, in the parenchymal form,
CNS lesions are found in the brainstem, basal ganglia,
and diencephalon. Innate immunity is most profoundly
activated in BD leading to CNS lesions exhibiting
infiltrating macrophages, neutrophils, and activated glial
cells [2,3].
NBD often presents with attack and remission periods
and a significant accumulation of disability can be observed
in some patients after a few attacks occurring in a short

time frame [4,5]. Cerebrospinal fluid (CSF) levels of IL-6
and increased CSF cell count are the most consistently
reported prognostic biomarkers [6]. IL-6 has also been
shown to decrease CSF in parallel to favorable treatment
response to tocilizumab [7]. Although CSF levels of IL-6,
IL-37, and BAFF have been found to be correlated with
disease activity in cross-sectional studies, the significance
of these mediators as disease monitoring biomarkers
has not been evaluated in longitudinal follow-up studies
[8–10]. Thus, biomarkers that predict clinical evolution
and long-term outcome of NBD are sorely needed for
improved treatment decisions.
In this context, neurofilament light chain (NFL) and
chitinase-3-like protein 1, which is also known as YKL40, have stood out as potential prognostic and monitoring
biomarkers in several neuroimmunological and
neurodegenerative disorders [11–13]. NFL is a neuronal
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cytoplasmic protein, which is found in axons and rises in
CSF in proportion to the degree of axonal damage. NFL
appears to be not only a biomarker of axonal damage
but also cognitive impairment in a variety of disorders
including multiple sclerosis (MS) and amyotrophic lateral
sclerosis [12]. Several studies have shown that CSF levels
of YKL-40, which is likely a marker of glial activity [14],
effectively discriminate different prognostic subgroups
of MS and predict the progression of disability [13,15].
Notably, an association between serum levels of YKL-40
and disease activity has been demonstrated in BD patients
[16–18]. Based on our proteomics and ELISA studies, we
have recently identified that CSF level of homeobox protein
Hox-B3 (HoxB3) may be used to predict conversion from
clinically isolated syndrome to MS alone or in combination
with YKL-40 [19,20]. Although the exact function of
HoxB3 in the CNS is not well understood, its growth
regulatory action and high expression in lymphocytes and
leukemia cells suggest that HoxB3 might be a marker of
immune cell activation [21,22].
In this study, we aimed to test whether NFL, HoxB3,
and YKL-40 could potentially be used for the prediction
of disease activity and clinical outcomes in NBD. For this
purpose, we measured levels of these biomarkers in CSF
samples obtained and stored during NBD attacks and looked
for potential correlations with clinical activity parameters of
NBD documented over several years of follow-up.

impairment was specifically interrogated during followup visits and was defined as attention deficit or memory
loss that interferes with the ability to perform daily
household activities (e.g., cooking, cleaning) and to work
and engage in social activities outside the home. The study
was approved by Institutional Review Board and informed
consent was received from each participant.

2. Materials and methods
2.1. Patients
Twenty-three NBD patients fulfilling the diagnostic
criteria for BD [23] were enrolled. Demographical and
clinical features of NBD patients are shown in Table 1.
CSF samples were obtained from all NBD patients during
an active episode. Typical features of parenchymal NBD
(unilateral or bilateral large hyperintense lesions extending
from brainstem to diencephalon and basal ganglia) and
cerebral venous thrombosis (nonparenchymal NBD)
were demonstrated by magnetic resonance imaging
(MRI) and magnetic resonance venography when
required. NBD patients with other coexisting disorders
and acute infections were excluded. None of the patients
were under immunosuppressive treatment during CSF
sampling. NBD patients were followed thereafter under a
standard treatment protocol including pulse intravenous
methylprednisolone during attacks and azathioprine. The
progression of disability was graded by a modified Rankin
score (mRS), which was recorded during CSF sampling
and the final follow-up visit. The difference between
the last and first mRS scores (∆ mRS) was calculated.
Duration of NBD, the total number of attacks, and the
number of attacks during the follow-up period (between
CSF sampling and final visit) were documented. Cognitive

3. Results

2.2. Elisa
All CSF samples were collected during NBD attacks
and stored at –80 °C until use. The levels of NFL (IBL
International, Hamburg, Germany, UD51001), YKL-40
(SunRed Biotechnology Company, Shanghai, China), and
HoxB3 (SunRed Biotechnology Company) were measured
by ELISA according to the manufacturer’s instructions.
Normal values of NFL were measured between 112 and
821 pg/mL as per the manufacturer’s instructions. Optical
densities were measured at 450 nm and concentrations
were calculated by reference to the standard curves.
2.3. Statistical analysis
A comparison of parametric data among patient
subgroups was conducted by Student’s t-test. mRS and
∆ mRS values were compared by Mann-Whitney U.
Categorical parameters were compared with chi-square
test. Correlation studies were accomplished by Spearman’s
correlation test. P-value below 0.05 was defined as
statistical significance.

3.1. Comparison of parenchymal and nonparenchymal
NBD patients
NBD patients (13 men and 10 women) had an average age (±
standard deviation) of 40.5 ± 14.9 years and were classified
as parenchymal NBD (n = 16) and nonparenchymal
NBD (n = 7). The average mRS recorded during attacks
(when CSF samples were obtained) was 1.5 ± 1.1 and was
increased to 1.9 ± 1.5 during a follow-up duration of 3.9 ±
1.3 years (range 2–6 years). Thirteen of 23 NBD patients
exhibited elevated mRS and 5 patients declared significant
cognitive impairment during follow-up (Table 1). While
8 NBD patients showed reduced mRS, mRS of 2 patients
remained identical throughout the follow-up period.
Parenchymal and nonparenchymal NBD patients
showed comparable age, gender, disease duration, and
follow-up duration. However, parenchymal NBD patients
had higher initial mRS, final mRS and number of attacks
in total and after CSF collection. Also, 12 of 13 NBD
patients with elevated mRS and all 5 NBD patients, who
developed significant cognitive impairment during
follow-up, were within the parenchymal group. CSF NFL,
HoxB3, and YKL-40 levels of parenchymal NBD patients
were significantly higher than those of nonparenchymal
patients (Table 2).
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Table 1. Clinical, demographic features and cerebrospinal fluid (CSF) measurements
of neuro-Behçet’s disease (NBD) patients.
Age

40.5 ± 14.9

Gender (men/women)

13/10

Parenchymal/non-parenchymal NBD

16/7

Duration of NBD (years)

11.7 ± 7.8

Follow-up after CSF collection (years)

3.9 ± 1.3

First mRS during CSF collection

1.5 ± 1.1

Final mRS

1.9 ± 1.5

Elevation of mRS during follow-up

13 patients

Total number of attacks

1.5 ± 0.7

Number of attacks during follow-up

0.3 ± 0.6

Patients with cognitive symptoms

5

CSF level of NFL (ng/L)

3401.6 ± 3876.5

CSF level of HoxB3 (ng/L)

3.3 ± 0.7

CSF level of YKL-40 (pg/mL)

1096.0 ± 91.6

Numerical data are denoted as mean ± standard deviation.
mRS: modified Rankin score; NFL: neurofilament light chain; HoxB3: homeobox
protein Hox-B3.
Table 2. Comparison of clinical, demographic features, and cerebrospinal fluid (CSF) measurements of neuro-Behçet’s disease (NBD)
patients with and without parenchymal involvement.
Parenchymal NBD (n = 16)

Nonparenchymal NBD (n = 7)

p-value

Age

42.3 ± 12.0

36.4 ± 20.5

0.250

Gender (men/women)

9/7

4/3

0.968

Duration of NBD (years)

12.0 ± 6.9

11.0 ± 10.3

0.411

Follow-up after CSF collection (years)

4.3 ± 1.4

3.0 ± 0.6

0.115

First mRS during CSF collection

1.8 ± 1.2

0.9 ± 0.7

0.012

Final mRS

2.6 ± 1.2

0.3 ± 0.8

<0.001

Elevation of mRS during follow-up

12 patients

1 patient

0.025

Total number of attacks

1.7 ± 0.8

1.0 ± 0.0

0.002

Number of attacks during follow-up

0.5 ± 0.6

0.0 ± 0.0

0.007

Patients with cognitive symptoms

5

0

0.095

CSF level of NFL (ng/L)

4583.9 ± 4125.8

699.1 ± 543.3

0.001

CSF level of HoxB3 (ng/L)

3.5 ± 0.8

3.0 ± 0.2

0.015

CSF level of YKL-40 (pg/mL)

1122.8 ± 97.9

1034.7 ± 22.2

0.002

Numerical data are denoted as mean ± standard deviation.
mRS: modified Rankin score; NFL: neurofilament light chain; HoxB3: homeobox protein Hox-B3.
Bold p values indicate statistical significance.

3.2. Comparison of NBD patients with and without
stable clinical course
To better evaluate the association of CSF biomarkers with
the clinical progression of NBD, patients were grouped as
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the elevated-mRS group showed a higher number of
patients with parenchymal involvement and cognitive
impairment and significantly elevated final mRS values
and attack numbers. Moreover, patients with increased
mRS displayed significantly elevated CSF NFL levels than
patients with a relatively stable disease course. By contrast,
CSF levels of HoxB3 and YKL-40 were comparable among
mRS subgroups (Table 3). The elevated-mRS group had
higher parenchymal NBD prevalence and a relatively
higher follow-up duration. When only parenchymal NBD
patients with and without mRS elevation were compared,
the NFL level difference between mRS subgroups ceased
to be significant (Table 4), suggesting that increased NFL
in the elevated mRS group was a reflection of higher
parenchymal NBD prevalence and follow-up duration in
this subgroup.
3.3. Comparison of NBD patients with higher and lower
CSF NFL levels
Since CSF HoxB3 and YKL-40 levels did not show any
association with clinical worsening, we focused on CSF
NFL levels for the remainder of our study. To have a better
insight into the association between CSF NFL levels and
clinical progression of NBD, patients with higher and lower
CSF NFL were compared. While patients with higher and
lower NFL levels showed comparable age, gender, NBD
duration, follow-up duration, the total number of attacks,
initial and final mRS scores, NBD patients with CSF NFL

levels of ≥1000 ng/L were more likely to have parenchymal
involvement, new attacks and cognitive impairment during
follow-up. As a matter of fact, NBD patients with CSF
NFL levels <1000 ng/L did not exhibit any NBD attacks or
symptoms of cognitive impairment in a follow-up duration
of 3.6 ± 1.2 years. CSF levels of HoxB3 and YKL-40 were
comparable among NBD patients with high and low NFL
levels (Table 5). When only parenchymal NBD patients
with high and low NFL levels were compared, similar
tendencies were observed. Despite having a relatively
younger age and reduced disease duration, parenchymal
NBD patients with a CSF NFL level of more than 1000
ng/L were more likely to develop cognitive impairment
and new attacks during follow-up (Table 6).
Next, we investigated potential correlations between
CSF NFL levels and clinical, demographic, and CSF
biomarker variables listed in Table 1. CSF NFL levels
were only correlated with disease duration (p = 0.009, R
= 0.612) and mRS at the last visit (p = 0.049, R = 0.400).
While, CSF HoxB3 levels were correlated with a number
of attacks during the follow-up (p = 0.010, R = 0.539),
CSF YKL-40 levels were not correlated with any of the
parametric variables. There were no correlations between
CSF biomarker levels versus age, disease duration, total
number of attacks, initial mRS and ∆ mRS. There were
also no correlations among CSF levels of NFL, HoxB3, and
YKL-40.

Table 3. Comparison of clinical, demographic features, and cerebrospinal fluid (CSF) measurements of neuro-Behçet’s disease (NBD)
patients with and without elevated mRS during follow-up.
NBD with stable mRS (n = 10)

NBD with elevated mRS (n = 13)

p-value

Age

36.5 ± 15.6

43.6 ± 14.1

0.137

Gender (men/women)

6/4

7/6

0.768

Parenchymal/nonparenchymal NBD

4/6

12/1

0.007

Duration of NBD (years)

11.5 ± 9.9

11.8 ± 6.2

0.457

Follow-up after CSF collection (years)

3.6 ± 1.3

4.1 ± 1.4

0.514

First mRS during CSF collection

1.6 ± 1.2

1.5 ± 1.1

0.389

Final mRS

0.6 ± 1.1

2.9 ± 1.0

<0.001

Total number of attacks

1.1 ± 0.3

1.8 ± 0.8

0.007

Number of attacks during follow-up

0.0 ± 0.0

0.6 ± 0.7

0.006

Patients with cognitive symptoms

1

4

0.231

CSF level of NFL (ng/L)

1848.1 ± 3022.0

4596.5 ± 4140.3

0.040

CSF level of HoxB3 (ng/L)

3.1 ± 0.4

3.5 ± 0.8

0.081

CSF level of YKL-40 (pg/mL)

1096.9 ± 131.7

1095.2 ± 48.6

0.485

Numerical data are denoted as mean ± standard deviation.
mRS: modified Rankin score; NFL: neurofilament light chain; HoxB3: homeobox protein Hox-B3.
Bold p values indicate statistical significance.
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Table 4. Comparison of clinical, demographic features, and cerebrospinal fluid (CSF) measurements of parenchymal neuro-Behçet’s
disease (NBD) patients with and without elevated mRS during follow-up.
NBD with stable mRS (n = 4)

NBD with elevated mRS (n = 12)

p value

Age

45.6 ± 14.0

41.2 ± 11.8

0.302

Gender (men/women)

3/1

6/6

0.383

Duration of NBD (years)

13.2 ± 9.1

11.6 ± 6.4

0.380

Follow-up after CSF collection (years)

4.3 ± 1.9

4.3 ± 1.4

0.960

First mRS during CSF collection

2.5 ± 1.3

1.6 ± 1.1

0.132

Final mRS

1.5 ± 1.3

3.0 ± 1.0

0.048

Total number of attacks

1.3 ± 0.5

1.9 ± 0.8

0.047

Number of attacks during follow-up

0.0 ± 0.0

0.6 ± 0.7

0.005

Patients with cognitive symptoms

1

4

0.755

CSF level of NFL (ng/L)

3513.8 ± 4545.6

4940.6 ± 4125.7

0.302

CSF level of HoxB3 (ng/L)

3.2 ± 0.7

3.5 ± 0.8

0.246

CSF level of YKL-40 (pg/mL)

1197.3 ± 170.3

1097.9 ± 49.7

0.165

Numerical data are denoted as mean ± standard deviation.
mRS: modified Rankin score; NFL: neurofilament light chain; HoxB3: homeobox protein Hox-B3.
Bold p values indicate statistical significance.
Table 5. Comparison of clinical, demographic features, and cerebrospinal fluid (CSF) measurements of neuro-Behçet’s disease (NBD)
patients with higher (<1000 ng/L) and lower (≥1000 ng/L) CSF NFL levels.

NBD with lower NFL (n = 10)

NBD with higher NFL (n = 13)

p-value

Age

44.6 ± 20.4

37.4 ± 8.2

0.155

Gender (men/women)

6/4

7/6

0.768

Parenchymal/nonparenchymal NBD

5/5

11/2

0.074

Duration of NBD (years)

14.5 ± 7.9

9.5 ± 7.3

0.068

Follow-up after CSF collection (years)

3.6 ± 1.2

4.1 ± 1.4

0.521

First mRS during CSF collection

1.5 ± 1.3

1.5 ± 1.1

0.470

Final mRS

1.5 ± 1.6

2.2 ± 1.5

0.136

Elevation of mRS during follow-up

4 patients

9 patients

0.161

Total number of attacks

1.4 ± 0.7

1.6 ± 0.8

0.286

Number of attacks during follow-up

0.0 ± 0.0

0.5 ± 0.7

0.013

Patients with cognitive symptoms

0

5

0.026

CSF level of NFL (ng/L)

545.6 ± 332.2

5598.5 ± 3929.5

<0.001

CSF level of HoxB3 (ng/L)

3.3 ± 0.7

3.3 ± 0.7

0.421

CSF level of YKL-40 (pg/mL)

1108.9 ± 131.4

1086.0 ± 46.6

0.305

Numerical data are denoted as mean ± standard deviation.
mRS: modified Rankin score; NFL: neurofilament light chain; HoxB3: homeobox protein Hox-B3.
Bold p values indicate statistical significance.
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Table 6. Comparison of clinical, demographic features, and cerebrospinal fluid (CSF) measurements of parenchymal neuro-Behçet’s
disease (NBD) patients with higher (<1000 ng/L) and lower (≥1000 ng/L) CSF NFL levels.
NBD with lower NFL (n = 5)

NBD with higher NFL (n = 11)

p-value

Age

50.7 ± 15.4

38.5 ± 8.4

0.079

Gender (men/women)

3/2

6/5

0.838

Duration of NBD (years)

14.3 ± 6.7

10.9 ± 7.0

0.194

Follow-up after CSF collection (years)

4.5 ± 1.2

4.2 ± 1.6

0.776

First mRS during CSF collection

2.2 ± 1.3

1.6 ± 1.1

0.216

Final mRS

2.6 ± 1.3

2.6 ± 1.2

0.480

Elevation of mRS during follow-up

3 patients

9 patients

0.350

Total number of attacks

1.6 ± 0.9

1.7 ± 0.8

0.420

Number of attacks during follow-up

0.0 ± 0.0

0.5 ± 0.7

0.027

Patients with cognitive symptoms

0

5

0.069

CSF level of NFL (ng/L)

690.8 ± 388.5

6353.5 ± 3801.4

<0.001

CSF level of HoxB3 (ng/L)

3.6 ± 0.9

3.4 ± 0.7

0.335

CSF level of YKL-40 (pg/mL)

1180.6 ± 160.6

1096.5 ± 40.3

0.155

Numerical data are denoted as mean ± standard deviation.
mRS: modified Rankin score; NFL: neurofilament light chain; HoxB3: homeobox protein Hox-B3.
Bold p values indicate statistical significance.

4. Discussion
In this study, we measured CSF levels of NFL, HoxB3,
and YKL-40 in NBD patients for the first time, to our
knowledge. We preferred CSF over serum measurements
since CSF levels of biomarkers are expected to be more
closely related to disease activity in inflammatory and
degenerative disorders. Moreover, we recently showed that
CSF HoxB3 and YKL-40 levels had a higher predictive
value than serum HoxB3 and YKL-40 levels in the
evaluation of disability progression in MS patients [20].
Several disease activity parameters including mRS value,
mRS elevation, the number of attacks, and cognitive
impairment were significantly increased in parenchymal
patients as compared to vascular NBD patients with
similar clinical and demographic features, as described
previously [4,5]. Likewise, parenchymal NBD patients
showed higher levels of all three biomarker candidates
than nonparenchymal patients. Higher CSF NFL, HoxB3,
and YKL-40 levels in parenchymal NBD may plausibly be a
reflection of elevated neuroaxonal degeneration, immune
system activation, and glial activation, respectively, in this
NBD subgroup.
An intriguing feature was that CSF YKL-40 levels
were highly elevated (>900 pg/mL) in all NBD patients
regardless of disease activity. This is in contrast with MS
patients of our outpatient clinic, who display CSF YKL-40
levels in an approximate range of 40–1200 pg/mL and an
average of around 700 pg/mL [20]. In the CNS, YKL-40
is mainly produced by activated infiltrating macrophages,

neutrophils and glial cells [24]. Critical molecular pathways
of innate immunity (e.g., inflammasome complex) are
significantly enhanced in NBD, particularly during clinical
attacks [25,26]. Therefore, homogeneously elevated YKL40 levels may be caused by highly increased glial activity
and infiltrating macrophages/neutrophils, which are
hallmarks of NBD pathology [2,3].
In MS, increased CSF NFL levels predict enhanced
disability in the upcoming years. Higher CSF NFL is usually
linked to more advanced disability and a greater likelihood
of cognitive dysfunction in MS [27]. Our results suggest
that CSF NFL may have similar power in the prediction
of forthcoming somatic and cognitive disability in NBD.
In both the total and parenchymal NBD groups, higher
NFL levels measured in the attack CSF corresponded to
an increased number of attacks, increased disability, and
occurrence of cognitive symptoms during follow-up. More
specifically, CSF NFL levels >1000 ng/L were associated
with the occurrence of new attacks and the emergence
of significant cognitive dysfunction in the forthcoming
∼3–4 years. By contrast, patients with CSF NFL levels of
less than 1000 ng/L did not display any attacks or cognitive
dysfunction during the same time period. HoxB3 levels
were only marginally correlated with attack numbers and
YKL-40 levels were not associated with any of the clinical
progression parameters decreasing the enthusiasm for
further investigation of these biomarkers in NBD.
Interestingly, there was no correlation between CSF NFL
levels versus mRS values and attack numbers documented
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during the NBD attack. This finding suggests that crosssectional NFL level is not a good indicator of NBD-related
disability accumulated in the past. This is the opposite of the
MS experience, which suggests that CSF NFL is correlated
with both cross-sectional and longitudinal and prospective
disability in MS patients [28].
It was also notable that NFL level was only marginally
correlated with an increase in mRS values during follow-up,
despite showing a stronger association with attack numbers
and cognitive dysfunction. This weak association with mRS,
mostly an indicator of somatic disability, might be because
this scoring system is not an ideal method for measuring
disability in BD/NBD. Since BD is a systemic disease, patients
may show physical impairment due to nonneurological or
noninflammatory factors, such as severe mechanical joint
problems or peripheral blood vessel occlusion [29,30]. Thus,
the absence of an NBD-specific disability scale is a major
obstacle in prognostic biomarker studies. Secondly, cognitive
impairment and brain atrophy might be developing in NBD
on a steady-state basis independently of neurological attacks,
increase in scales of somatic disability, or presence of MRI
lesions [31,32]. Moreover, brain volume loss may be observed
in NBD in brain regions (e.g., hippocampus) that are not
among typical lesion sites of NBD [31]. As demonstrated in
MS patients, continuously enhanced glial activity might be
one of the driving forces behind this concealed progression
of cognitive disability, since enhanced microglial activity
does not manifest in the form of clinical exacerbations
and MRI lesions [33]. Proteolytic enzymes and neurotoxic
cytokines produced by M1 microglia may lead to chronic and
insidious neuronal loss leading to cognitive dysfunction in
due time [34]. This possibility prompts the requirement for

nonradiological and molecular-based prognostic biomarkers
such as NFL.
In our study, diagnosis of cognitive dysfunction was
based on patients’ statements and complaints and thus we
could only pinpoint patients with the most severe cognitive
problems. Thus, a major limitation of our study was the
absence of formal cognitive tests that would more accurately
diagnose cognitive dysfunction and also single outpatients
with milder cognitive impairment. Likewise, the absence
of imaging data obtained during the final follow-up visit
prevented assessment of the association between NFL levels
and brain atrophy.
In brief, our results suggest that CSF NFL levels higher
than 1000 ng/L might indicate an unfavorable prognosis
in NBD and thus these patients should be more closely
monitored and alternative treatment options such as
cyclophosphamide should be considered. These results
should be further validated by higher numbers of patients
with longer follow-up durations.
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